Delcath Systems (DCTH) PT Raised to $24 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Delcath Systems (NASDAQ: DCTH) to $24.00 (from $22.00) while maintaining a Buy rating.

The analyst commented: "On March 6, Delcath reported 4Q24 financial results and provided a corporate update. The company continues to focus on adding HEPZATO treatment sites as well as geographic expansion. The company activated three new sites in 4Q24 with another two sites activated since the start of 2025, bringing the total number of centers to date to 16. The company reported that one additional center has scheduled a first treatment in March and eight more centers are accepting referrals. We believe this represents a strong pipeline that bodes well for growth in 2025. Management has set the goal of 30 total active centers by the end of 2025, with a larger portion of activations projected for the second half of the year. Delcath intends to expand from four to six sales regions and is increasing its commercial team in order to support the territory expansion. Regarding ex-US business, the company expects modest but steady growth in Europe, targeting to achieve financial breakeven as they expect the European centers to support clinical trials and aid in generating publications. The company reported $15.1M in total revenue for 4Q24, a 35% growth QoQ from $11.2M in 3Q24. We currently project $338.7M total revenues in 2032, growing from $82.3M in 2025. Reiterate Buy rating and increase PT to $24 from $22."

You May Also Be Interested In

• Tradeweb Markets (TW) PT Lowered to $151 at Raymond James
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M
• Altria (MO) PT Raised to $79 at UBS Ahead of Product Launches